- Article
Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab
- Marina Fabbi,
- Delfina Costa,
- Daniela Russo,
- Laura Arenare,
- Gabriele Gaggero,
- Simona Signoriello,
- Giovanni Scambia,
- Carmela Pisano,
- Nicoletta Colombo and
- Nunzia Simona Losito
- + 12 authors
To find prognostic factors for advanced ovarian cancer patients undergoing first-line therapy with carboplatin, paclitaxel and bevacizumab, we investigated the expression of a disintegrin and metalloprotease 17 (ADAM17) in cancer tissues. ADAM17 has...